Effects of Pituitary Adenylate Cyclase Activating Polypeptide on Cell Death. 2022

Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
Department of Anatomy, MTA-PTE PACAP Research Team, University of Pecs Medical School, 7624 Pecs, Hungary.

Pituitary adenylate cyclase activating polypeptide (PACAP) was first isolated as a hypothalamic peptide based on its efficacy to increase adenylate cyclase (AC) activity. It has a widespread distribution throughout the body including the nervous system and peripheral organs, where PACAP exerts protective effects both in vivo and in vitro through its anti-apoptotic, anti-inflammatory, and antioxidant functions. The aim of the present paper was to review the currently available literature regarding the effects of PACAP on cell death in vitro in neural and non-neural cells. Among others, its effect on apoptosis can be detected in cerebellar granule cells against different toxic stimuli. Different neural cell types from the cerebral cortex are also prevented from cell death. PACAP also shows effects on cell death in cells belonging to the peripheral nervous system and protects both neural and non-neural cells of sensory organs. In addition, cell survival-promoting effect can be observed in different peripheral organ systems including cardiovascular, immune, respiratory, gastrointestinal, urinary, and reproductive systems. The studies summarized here indicate its noteworthy effect on cell death in different in vitro models, suggesting PACAP's potential therapeutic usage in several pathological conditions.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D016923 Cell Death The termination of the cell's ability to carry out vital functions such as metabolism, growth, reproduction, responsiveness, and adaptability. Death, Cell
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D051219 Pituitary Adenylate Cyclase-Activating Polypeptide A multi-function neuropeptide that acts throughout the body by elevating intracellular cyclic AMP level via its interaction with PACAP RECEPTORS and VASOACTIVE INTESTINAL PEPTIDE RECEPTOR. Although first isolated from hypothalamic extracts and named for its action on the pituitary, it is widely distributed in the central and peripheral nervous systems. PACAP is important in the control of endocrine and homeostatic processes, such as secretion of pituitary and gut hormones and food intake. PACAP,PACAP-27,PACAP-38,PACAP27,PACAP38,Pituitary Adenylate Cyclase Activating Polypeptide,Pituitary Adenylate Cyclase Activating Polypeptide 27,Pituitary Adenylate Cyclase Activating Polypeptide 38
D051237 Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I A pituitary adenylate cyclase-activating peptide receptor subtype that is found in the HYPOTHALAMUS; BRAIN STEM; PITUITARY GLAND; ADRENAL GLAND; PANCREAS; and TESTES and has a high affinity only for PACAP. PACAP Receptors, Type I,Pituitary Adenylate Cyclase-Activating Peptide Receptor Type I,PAC1 Receptor,PACAP Type I Receptor,PACAPR-1 Protein,PACAPR 1 Protein,Pituitary Adenylate Cyclase Activating Peptide Receptor Type I

Related Publications

Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
December 1998, Annales d'endocrinologie,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
November 2012, Journal of molecular neuroscience : MN,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
October 2001, American journal of physiology. Heart and circulatory physiology,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
December 2014, Annals of clinical and translational neurology,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
July 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
September 1993, Regulatory peptides,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
February 2003, American journal of physiology. Regulatory, integrative and comparative physiology,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
January 2011, Current pharmaceutical design,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
May 2018, Neurotoxicology,
Gabriella Horvath, and Dora Reglodi, and Eszter Fabian, and Balazs Opper
July 2000, The Journal of comparative neurology,
Copied contents to your clipboard!